Author

L. Rui

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

C. M. Capitini· 2 shared D. P. Turicek· 2 shared F. Zhu· 2 shared N. J. Hess· 2 shared S. P. Rinella· 2 shared A. E. Quamine· 1 shared A. Russell· 1 shared A. S. Feils· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. M. Capitini

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expression

S. P. Rinella, H. C. Bell, N. J. Hess, N.-M. Hoang, T. T. Nguyen, D. P. Turicek, L. Shi, L. Rui, J. L. LaBelle, C. M. Capitini

This study shows that combining fedratinib and venetoclax effectively kills B-ALL cells with high FLT3 expression, both in vitro and in vivo.

bioRxiv · Jun 7, 2023 · PreprintCancer Biology

CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration

K. L. Walker, S. P. Rinella, N. J. Hess, D. P. Turicek, S. A. Kabakov, F. Zhu, M. N. Bouchlaka, S. L. Olson, M. M. Cho, A. E. Quamine, A. S. Feils, T. B. Gavcovich, L. Rui, C. M. Capitini

This study shows that combining JAK1/2 and BCL2 inhibitors in T-ALL leads to CNS infiltration, which is reduced by adding a CXCR4 inhibitor.

bioRxiv · Mar 6, 2021Cancer Biology

Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice

E. Masle-Farquhar, A. Russell, Y. Li, F. Zhu, L. Rui, R. Brink, C. Goodnow

This study shows that loss-of-function mutations in Fbxo10 do not increase BCL2 or B lymphocyte numbers in mice, suggesting redundant regulation of BCL2 by other ubiquitin ligases.

bioRxiv · Aug 5, 2020Immunology